Groups

Groups
E-mail Print PDF

2012

Ferber M, Zoete V, Michielin O.
T-cell receptors binding orientation over peptide/MHC class I is driven by long-range interactions.
PLoS ONE 2012, 2012, 7, e5194


Röhrig UF, Majjigapu SR, Grosdidier A, Bron S, Stroobant V, Pilotte L, Colau D, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.
Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition.
J. Med. Chem., 2012, 14, 5270-90.


Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Luescher I, Rufer N, Michielin O.
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.
J. Biol. Chem., 2012, 287, 23068-78.


Gfeller D, Michielin O, Zoete V.
Expanding molecular modeling and design tools to non-natural sidechains.
J. Comput. Chem. 2012, 33, 1525-35.


Johansson MU, Zoete V, Michielin O, Guex N.
Defining and searching for structural motifs using DeepView/Swiss-PdbViewer.
BMC Bioinformatics. 2012, 13, 173.


Buey RM, Sen I, Kortt O, Mohan R, Gfeller D, Veprintsev D, Kretzschmar I, Scheuermann J, Neri D, Zoete V, Michielin O, de Pereda JM, Akhmanova A, Volkmer R, Steinmetz MO.
Sequence Determinants of a Microtubule Tip Localization Signal (MtLS).
J. Biol. Chem., 2012, 287, 28227-42.


Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O, Speiser DE.
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
PLoS One., 2012, 7, e30852.


Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE.
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.
Int. J. Cancer., 2012, 130, 2607-17.


Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R.
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Oncol Rep. 2012, 28, 654-8.


von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK).
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Ann. Oncol., 2012, 23, 531-6.


Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, Michielin O, Bachmann MF, Speiser DE.
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Eur J Immunol. 2012, 11, 3049-61.


Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O.
Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
J Clin Oncol. 2012, 30, e156-9.


 

google analytics